BVF Inc. IL Has $14.89 Million Stock Position in Silence Therapeutics Plc (NASDAQ:SLN)
BVF Inc. IL Has $14.89 Million Stock Position in Silence Therapeutics Plc (NASDAQ:SLN)
BVF Inc. IL raised its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN – Get Rating) by 126.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,508,416 shares of the company's stock after buying an additional 841,750 shares during the quarter. BVF Inc. IL owned about 4.20% of Silence Therapeutics worth $14,888,000 as of its most recent SEC filing.
根據該公司在最近向證券交易委員會提交的 13F 表格中，BVF Inc. IL 在第三季度增加了其沉默治療有限公司（NASDAQ：SLN-獲得評級）的股份持有權 126.3％。該基金在本季度額外購入 841,750 股股份後，擁有該公司股票的 1,508,416 股股份。作為最近的 SEC 文件，BVF 公司 IL 擁有約 4.20％ 的沉默治療，價值 14,888,000 美元。
Several other hedge funds also recently modified their holdings of SLN. Goldman Sachs Group Inc. lifted its position in shares of Silence Therapeutics by 27.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company's stock worth $18,350,000 after acquiring an additional 205,815 shares during the period. Citadel Advisors LLC acquired a new stake in Silence Therapeutics during the second quarter worth $136,000. UBS Oconnor LLC increased its holdings in Silence Therapeutics by 176.4% in the 3rd quarter. UBS Oconnor LLC now owns 79,636 shares of the company's stock valued at $786,000 after buying an additional 50,820 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of Silence Therapeutics by 120.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 550,875 shares of the company's stock valued at $5,528,000 after buying an additional 300,875 shares in the last quarter.
其他幾個對沖基金最近也修改了他們對 SLN 的持有量。高盛集團公司在第一季度上升了 27.1％ 的沉默治療股份的地位。在期內，高盛集團現在擁有該公司股票 965,815 股價值 18,350,000 美元的 965,815 股股份。城堡顧問有限責任公司在第二季度收購了沉默治療的新股份 $136,000.瑞銀奧康納有限責任公司在第三季度將其在沉默治療的持有量增加了 176.4％。瑞銀奧康納有限責任公司在期內額外購買 50,820 股股份後，現在擁有該公司 79,636 股價值 786,000 美元的股票。最後，Point72 資產管理有限責任公司在第三季度將其沉默治療股份的股份增加了 120.4％。在上一季度額外購買 300,875 股股份後，Point72 資產管理有限責任公司股票的 550,875 股股份，價值 5,528,000 美元。
Analyst Upgrades and Downgrades
分析師升級和降級
A number of analysts recently weighed in on SLN shares. Morgan Stanley started coverage on shares of Silence Therapeutics in a research note on Friday, December 9th. They issued an "equal weight" rating and a $18.00 target price on the stock. Robert W. Baird increased their target price on Silence Therapeutics from $50.00 to $53.00 in a report on Thursday, January 26th. HC Wainwright decreased their price target on Silence Therapeutics from $95.00 to $80.00 and set a "buy" rating on the stock in a research note on Tuesday, December 6th. Finally, Chardan Capital cut their price objective on Silence Therapeutics from $33.00 to $29.00 and set a "buy" rating for the company in a report on Thursday, November 17th.
一些分析師最近對 SLN 股票進行了權衡。摩根士丹利開始報導沉默治療的股份在研究筆記上週五, 12 月 9 日.他們發布了「同等權重」評級和 18.00 美元的股票目標價格。1 月 26 日（星期四）的一份報告中，羅伯特 ·W· 貝爾德將沉默治療的目標價格從 $50.00 提高到 $53.00 美元。韋賴特韋恩萊特將沉默治療的目標價格從 95.00 美元降至 80.00 美元，並在 12 月 6 日（星期二）的研究報告中設定了股票的「買入」評級。最後，查丹資本將沉默治療的價格目標從 33.00 美元降至 29.00 美元，並在 11 月 17 日（星期四）的報告中為該公司設定了「買入」評級。
Silence Therapeutics Stock Performance
沉默治療股票表現
SLN traded up $0.20 during mid-day trading on Tuesday, reaching $12.01. The stock had a trading volume of 22,734 shares, compared to its average volume of 39,489. The firm's fifty day simple moving average is $13.70 and its two-hundred day simple moving average is $12.60. The stock has a market capitalization of $359.46 million, a P/E ratio of -7.77 and a beta of 0.85. Silence Therapeutics plc has a 52 week low of $7.80 and a 52 week high of $22.00.
SLN 在周二中間交易期間交易上漲了 0.20 美元，達到 12.01 美元。該股的交易量為 22,734 股，與其平均交易量為 39,489 股相比。該公司的五十天簡單移動平均線為 13.70 美元，其 200 日簡單移動平均線為 12.60 美元。該股的市值為 35946 萬美元，市盈率為 -7.77，貝塔值為 0.85。沉默治療有限公司的 52 周低點為 7.80 美元，52 周高點為 22.00 美元。
About Silence Therapeutics
關於沉默療法
(Get Rating)
(取得評分)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Silence Theraptics plc 是一家生物技術公司，專注於在血液學，心血管和其他罕見和代謝適應症中新穎核糖核酸（RNA）治療藥物的發現和開發。該公司的平台包括 MrNai Galnac 寡核苷酸發現平台，旨在準確地靶向肝臟中的特定疾病相關基因。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Silence Therapeutics (SLN)
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
- Is Target Stock Aiming For A Breakout In 2023?
- How Long Can Wingstop Stock Continue to Defy Gravity?
- 獲取有關沉默治療學（SLN）的研究報告的免費副本
- 亞馬遜是藍籌股嗎？
- 西方石油拉回甜蜜點
- 您應該乘坐皇家加勒比國際遊輪嗎？
- 目標股票是否瞄準在 2023 年突破？
- 永保股票可以繼續抗拒重力多久？
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收沉默治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關沉默治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。